biostudies-literatureHossen MNUniversity of Oklahoma Stephenson Cancer CenterNational Cancer Institute Cancer CenterBiostatistics and Research Design Shared ResourceOffice of Cancer ResearchInstitutional Development Award (IDeA)NCI NIH HHSOklahoma Medical Research Foundation (OMRF)NIGMS NIH HHSUniversity of Oklahoma Health Sciences Centere2200491https://www.ebi.ac.uk/biostudies/studies/S-EPMC9631030biostudies-literatureUnknown9(31)By exploiting the self-therapeutic properties of gold nanoparticles (GNPs) a molecular axis that promotes the growth of high-grade serous ovarian cancer (HGSOC), one of the deadliest gynecologic malignancies with poorly understood underlying molecular mechanisms, has been identified. The biodistribution and toxicity of GNPs administered by intravenous or intraperitoneal injection, both as a single dose or by repeated dosing over two weeks are first assessed; no biochemical or histological toxicity to vital organs is found. Using an orthotopic patient-derived xenograft (PDX) model of HGSOC, the authors then show that GNP treatment robustly inhibits tumor growth. Investigating the molecular mechanisms underlying the GNP efficacy reveals that GNPs downregulate insulin growth factor binding prAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth.PMC9631030P20GM135009P30CA225500R01 CA136494P30 CA2255202048130P20 GM103639Fung KMBieniasz MDwivedi SKDBhattacharya RXu CWang LAsfa SElechalwar CKGulla SKWilhelm SDey AZhang YRao GSheth VRobertson JDMukherjee PHossen MNfalseGold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth.By exploiting the self-therapeutic properties of gold nanoparticles (GNPs) a molecular axis that promotes the growth of high-grade serous ovarian cancer (HGSOC), one of the deadliest gynecologic malignancies with poorly understood underlying molecular mechanisms, has been identified. The biodistribution and toxicity of GNPs administered by intravenous or intraperitoneal injection, both as a single dose or by repeated dosing over two weeks are first assessed; no biochemical or histological toxicity to vital organs is found. Using an orthotopic patient-derived xenograft (PDX) model of HGSOC, the authors then show that GNP treatment robustly inhibits tumor growth. Investigating the molecular mechanisms underlying the GNP efficacy reveals that GNPs downregulate insulin growth factor binding pr2022-01-01T00:00:00Z2022 Nov2025-04-05T12:34:07.501Z2025-02-19T00:31:37.459ZS-EPMC96310303610421510.1002/advs.202200491